Antiviral Activity of the PropylamylatinTM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions
Open Access
- 5 March 2021
- Vol. 13 (3), 415
- https://doi.org/10.3390/v13030415
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of novel coronavirus disease 2019 (COVID-19), has become a severe threat to global public health. There are currently no antiviral therapies approved for the treatment or prevention of mild to moderate COVID-19 as remdesivir is only approved for severe COVID-19 cases. Here, we evaluated the antiviral potential of a Propylamylatin formula, which is a mixture of propionic acid and isoamyl hexanoates. The Propylamylatin formula was investigated in gaseous and liquid phases against 1 mL viral suspensions containing 105 PFU of SARS-CoV-2. Viral suspensions were sampled at various times post-exposure and infectious virus was quantified by plaque assay on Vero E6 cells. Propylamylatin formula vapors were effective at inactivating infectious SARS-CoV-2 to undetectable levels at room temperature and body temperature, but the decline in virus was substantially faster at the higher temperature (15 min versus 24 h). The direct injection of liquid Propylamylatin formula into viral suspensions also completely inactivated SARS-CoV-2 and the rapidity of inactivation occurred in an exposure dependent manner. The overall volume that resulted in 90% viral inactivation over the course of the direct injection experiment (EC90) was 4.28 µls. Further investigation revealed that the majority of the antiviral effect was attributed to the propionic acid which yielded an overall EC90 value of 11.50 µls whereas the isoamyl hexanoates provided at most a 10-fold reduction in infectious virus. The combination of propionic acid and isoamyl hexanoates was much more potent than the individual components alone, suggesting synergy between these components. These findings illustrate the therapeutic promise of the Propylamylatin formula as a potential treatment strategy for COVID-19 and future studies are warranted.Keywords
Funding Information
- EcoPlanet Environmental LLC (NA)
This publication has 21 references indexed in Scilit:
- High-performance Countercurrent Chromatography to Access Rhodiola rosea Influenza Virus Inhibiting ConstituentsPlanta Medica, 2020
- Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and ManagementClinical Gastroenterology and Hepatology, 2020
- Natural products against acute respiratory infections: Strategies and lessons learnedJournal of Ethnopharmacology, 2020
- Complementary and alternative medicine utilisation for the management of acute respiratory tract infection in children: A systematic reviewComplementary Therapies in Medicine, 2018
- Natural Products as Sources of New Drugs from 1981 to 2014Journal of Natural Products, 2016
- Antiviral drug discovery: broad-spectrum drugs from natureNatural Product Reports, 2014
- Volatile antimicrobials from Muscodor crispans, a novel endophytic fungusMicrobiology, 2010
- Ethno-diversity within current ethno-pharmacology as part of Israeli traditional medicine – A reviewJournal of Ethnobiology and Ethnomedicine, 2006
- New endophytic isolates of Muscodor albus, a volatile-antibiotic-producing fungusMicrobiology, 2004
- Volatile antimicrobials from Muscodor albus, a novel endophytic fungusMicrobiology, 2001